<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03742349</url>
  </required_header>
  <id_info>
    <org_study_id>CADPT01A12101C</org_study_id>
    <secondary_id>2018-002244-82</secondary_id>
    <nct_id>NCT03742349</nct_id>
  </id_info>
  <brief_title>Study of Safety and Efficacy of Novel Immunotherapy Combinations in Patients With Triple Negative Breast Cancer (TNBC).</brief_title>
  <official_title>A Phase Ib, Multicenter, Open-label Dose Escalation and Expansion Platform Study of Select Immunotherapy Combinations in Adult Patients With Triple-negative Breast Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Novartis Pharmaceuticals</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Novartis</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a Phase Ib, open label, dose escalation study of spartalizumab + LAG525 in
      combination with NIR178, capmatinib, MCS110, or canakinumab, followed by a dose expansion in
      adult patients with advanced or metastatic TNBC.

      During the dose-escalation part of each treatment arm, patients will be treated with fixed
      doses of spartalizumab + LAG525 in combination with partner investigational drugs to be
      escalated until the MTD is reached or a lower RDE is established: NIR178, capmatinib, MCS110,
      or canakinumab. It is anticipated that other partner study drugs may be added in the future
      by protocol amendment.

      After the determination of the MTD/RDE for a particular treatment arm, dose expansion may
      begin in that arm in order to further assess safety, tolerability, PK/PD, and anti-tumor
      activity of each combination at the MTD/RDE. Dose expansion arms may initiate only after
      consideration by the Investigators and Novartis of all available toxicity information, the
      assessment of risk to future patients from the BLRM, and the available PK, preliminary
      efficacy, and PD information. There is no requirement for dose-escalation treatment arms
      reaching an MTD/RDE to proceed to dose expansion.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">January 31, 2019</start_date>
  <completion_date type="Anticipated">January 17, 2022</completion_date>
  <primary_completion_date type="Anticipated">January 17, 2022</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Incidence of Adverse Events (AEs) and Serious Adverse Events (SAEs) as a measure of safety</measure>
    <time_frame>at month 18</time_frame>
    <description>Month 18 is assumed to be study end</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Severity of Adverse Events (AEs) and Serious Adverse Events (SAEs) as a measure of safety</measure>
    <time_frame>at month 18</time_frame>
    <description>Month 18 is assumed to be study end</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Incidence of dose limiting toxicities (DLTs) of treatment (Escalation only)</measure>
    <time_frame>at Day 28</time_frame>
    <description>end of first cycle</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Frequency of dose interuptions</measure>
    <time_frame>at month 18</time_frame>
    <description>Month 18 is assumed to be study end</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Frequency of dose reductions</measure>
    <time_frame>at month 18</time_frame>
    <description>Month 18 is assumed to be study end</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Dose intensities</measure>
    <time_frame>at month 18</time_frame>
    <description>Month 18 is assumed to be study end</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Best overall response (BOR)</measure>
    <time_frame>at month 18</time_frame>
    <description>Month 18 is assumed to be study end</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progression free survival (PFS) per RECIST v1.1 and iRECIST</measure>
    <time_frame>at month 18</time_frame>
    <description>Month 18 is assumed to be study end</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Presence of anti-spartalizumab antibodies</measure>
    <time_frame>at Day 1, Day 29, Day 57, Day 85, Day 113, Day 141, Day 197, Day 253, Day 309 and EOT</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Presence of anti-LAG525 antibodies</measure>
    <time_frame>at Day 1, Day 29, Day 57, Day 85, Day 113, Day 141, Day 197, Day 253, Day 309 and EOT</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Presence of anti-MCS110 antibodies</measure>
    <time_frame>at Day 1, Day 29, Day 57, Day 85, Day 113, Day 141, Day 197, Day 253, Day 309 and EOT</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Presence of anti-canakinumab antibodies</measure>
    <time_frame>at Day 1, Day 29, Day 57, Day 85, Day 113, Day 141, Day 197, Day 253, Day 309 and EOT</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Serum concentration of spartalizumab, LAG525, MCS110, canakinumab</measure>
    <time_frame>at Day 1, Day 8, Day 15, Day 29, Day 57, Day 65, Day 70, Day 85, Day 113, Day 141, Day 197, Day 253, Day 309 and EOT</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Plasma concentration of NIR178, NJI675, capmatinib</measure>
    <time_frame>at Day 1, Day 29, Day 57, Day 85, Day 113, Day 141, Day 197, Day 253, Day 309 and EOT</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PK parameter (Tmax) of spartalizumab</measure>
    <time_frame>at month 12</time_frame>
    <description>cycle 12</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PK parameter (Cmax) of spartalizumab</measure>
    <time_frame>at month 12</time_frame>
    <description>cycle 12</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PK parameter (AUC) of spartalizumab</measure>
    <time_frame>at month 12</time_frame>
    <description>cycle 12</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PK parameter (Tmax) of LAG525</measure>
    <time_frame>at month 12</time_frame>
    <description>cycle 12</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PK parameter (Cmax) of LAG525</measure>
    <time_frame>at month 12</time_frame>
    <description>cycle 12</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PK parameter (AUC) of LAG525</measure>
    <time_frame>at month 12</time_frame>
    <description>cycle 12</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PK parameter (Tmax) of NIR178</measure>
    <time_frame>at month 12</time_frame>
    <description>cycle 12</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PK parameter (Cmax) of NIR178</measure>
    <time_frame>at month 12</time_frame>
    <description>cycle 12</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PK parameter (AUC) of NIR178</measure>
    <time_frame>at month 12</time_frame>
    <description>cycle 12</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PK parameter (Tmax) of capmatinib</measure>
    <time_frame>at month 12</time_frame>
    <description>cycle 12</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PK parameter (Cmax) of capmatinib</measure>
    <time_frame>at month 12</time_frame>
    <description>cycle 12</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PK parameter (AUC) of capmatinib</measure>
    <time_frame>at month 12</time_frame>
    <description>cycle 12</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PK parameter (Tmax) of MCS110</measure>
    <time_frame>at month 12</time_frame>
    <description>cycle 12</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PK parameter (Cmax) of MCS110</measure>
    <time_frame>at month 12</time_frame>
    <description>cycle 12</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PK parameter (AUC) of MCS110</measure>
    <time_frame>at month 12</time_frame>
    <description>cycle 12</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PK parameter (Tmax) of canakinumab</measure>
    <time_frame>at month 12</time_frame>
    <description>cycle 12</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PK parameter (Cmax) of canakinumab</measure>
    <time_frame>at month 12</time_frame>
    <description>cycle 12</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PK parameter (AUC) of canakinumab</measure>
    <time_frame>at month 12</time_frame>
    <description>cycle 12</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes from baseline of PD markers in tumor tissue (TILs, CD8, PD-L1, LAG-3)</measure>
    <time_frame>at baseline and at Day 43</time_frame>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Anticipated">220</enrollment>
  <condition>Triple Negative Breast Cancer (TNBC)</condition>
  <arm_group>
    <arm_group_label>1: spartalizumab + LAG525 + NIR178</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>phase Ib (escalation and expansion)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2: spartalizumab +LAG525 +capmatinib</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>phase Ib (escalation and expansion)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>3: spartalizumab + LAG525 + MCS110</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>phase Ib (escalation and expansion)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>4: spartalizumab +LAG525 +canakinumab</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>phase Ib (escalation and expansion)</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>spartalizumab</intervention_name>
    <description>LIVI (Liquid in vial) Concentrate for Solution for infusion</description>
    <arm_group_label>1: spartalizumab + LAG525 + NIR178</arm_group_label>
    <arm_group_label>2: spartalizumab +LAG525 +capmatinib</arm_group_label>
    <arm_group_label>3: spartalizumab + LAG525 + MCS110</arm_group_label>
    <arm_group_label>4: spartalizumab +LAG525 +canakinumab</arm_group_label>
    <other_name>PDR001</other_name>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>LAG525</intervention_name>
    <description>LAG525 LIVI (Liquid in vial) Concentrate for Solution for infusion</description>
    <arm_group_label>1: spartalizumab + LAG525 + NIR178</arm_group_label>
    <arm_group_label>2: spartalizumab +LAG525 +capmatinib</arm_group_label>
    <arm_group_label>3: spartalizumab + LAG525 + MCS110</arm_group_label>
    <arm_group_label>4: spartalizumab +LAG525 +canakinumab</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>NIR178</intervention_name>
    <description>Capsule</description>
    <arm_group_label>1: spartalizumab + LAG525 + NIR178</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>capmatinib</intervention_name>
    <description>Tablet</description>
    <arm_group_label>2: spartalizumab +LAG525 +capmatinib</arm_group_label>
    <other_name>INC280</other_name>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>MCS110</intervention_name>
    <description>LIVI (Liquid in vial) Concentrate for Solution for infusion</description>
    <arm_group_label>3: spartalizumab + LAG525 + MCS110</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>canakinumab</intervention_name>
    <description>LIVI (Liquid in vial) Solution for injection</description>
    <arm_group_label>4: spartalizumab +LAG525 +canakinumab</arm_group_label>
    <other_name>ACZ885</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Main Inclusion Criteria:

          -  Patients with advanced/metastatic TNBC (defined as HER-2 negative with &lt;1% of tumor
             cell nuclei immunoreactive for estrogen receptor (ER) and progesterone receptor (PR)),
             with measurable disease as determined by RECIST version 1.1 (refer to Appendix 16.1).
             Tumor lesions previously irradiated or subjected to other loco-regional therapy will
             only be considered measurable if there is documented disease progression at the
             treated site prior to study entry.

          -  Patients should have received standard chemotherapy for advanced or metastatic disease
             but should not have received more than 2 prior lines of chemotherapy. Neoadjuvant or
             adjuvant chemotherapy will count as one prior line.

          -  Patients must have received prior systemic treatment that included taxane-based
             chemotherapy for neoadjuvant or metastatic disease.

          -  Patients must have a site of disease amenable to core needle biopsy, and be a
             candidate for tumor biopsy according to the treating institution's guidelines.
             Patients must be willing to undergo a new tumor biopsy at screening, and during
             therapy on the study. Exceptions may be considered after documented discussion with
             Novartis. Patients with available archival tumor tissue obtained ≤6 months prior to
             study treatment initiation do not need to undergo a new tumor biopsy at screening, if
             the patient has not received any anti-cancer therapy since the biopsy was taken, and
             if adequate tissue is available.

        Main exclusion criteria applicable to all treatment arms:

          -  Patient has received prior treatment with anti-LAG-3, anti-PD-1, anti-PD-L1, or
             anti-PD-L2 antibody (any line of therapy).

          -  Presence of symptomatic central nervous system (CNS) metastases, or CNS metastases
             that require local CNS-directed therapy (such as radiotherapy or surgery), or
             increasing doses of corticosteroids within 2 weeks prior to initiating study
             treatment.

          -  History of severe hypersensitivity reactions to any ingredient of study drug(s) and
             other mAbs and/or their excipients.

          -  Impaired cardiac function or clinically significant cardiac disease.

          -  HIV infection.

          -  Patients with active hepatitis B virus (HBV) or hepatitis C virus (HCV) infection,
             including those with inactive disease for patients receiving either capmatinib, MCS110
             or canakinumab.

          -  Active, known or suspected autoimmune disease.

          -  History of or current interstitial lung disease or pneumonitis grade ≥ 2.

          -  Subjects with tuberculosis (TB), for patients receiving either MCS110 or canakinumab.

        Other eligibility criteria apply.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Novartis Pharmaceuticals</last_name>
    <phone>1-888-669-6682</phone>
    <email>novartis.email@novartis.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Novartis Pharmaceuticals</last_name>
    <phone>+41613241111</phone>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02114</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10032</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Nashville</city>
        <state>Tennessee</state>
        <zip>37203</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Westmead</city>
        <state>New South Wales</state>
        <zip>2145</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Shatin, New Territories</city>
        <country>Hong Kong</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Tel Aviv</city>
        <zip>6423906</zip>
        <country>Israel</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Milano</city>
        <state>MI</state>
        <zip>20133</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Milano</city>
        <state>MI</state>
        <zip>20141</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Kashiwa</city>
        <state>Chiba</state>
        <zip>277 8577</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Amsterdam</city>
        <zip>1066 CX</zip>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Singapore</city>
        <zip>119074</zip>
        <country>Singapore</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Singapore</city>
        <zip>169610</zip>
        <country>Singapore</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Barcelona</city>
        <state>Catalunya</state>
        <zip>08035</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Valencia</city>
        <state>Comunidad Valenciana</state>
        <zip>46010</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>Australia</country>
    <country>Hong Kong</country>
    <country>Israel</country>
    <country>Italy</country>
    <country>Japan</country>
    <country>Netherlands</country>
    <country>Singapore</country>
    <country>Spain</country>
    <country>United States</country>
  </location_countries>
  <verification_date>January 2020</verification_date>
  <study_first_submitted>November 12, 2018</study_first_submitted>
  <study_first_submitted_qc>November 12, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">November 15, 2018</study_first_posted>
  <last_update_submitted>January 17, 2020</last_update_submitted>
  <last_update_submitted_qc>January 17, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">January 21, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Phase Ib, TNBC, advanced, metastatic, immunotherapy, PDR001,</keyword>
  <keyword>LAG525, NIR178, INC280, MCS110, ACZ885</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Breast Neoplasms</mesh_term>
    <mesh_term>Triple Negative Breast Neoplasms</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

